journal article·2026-03-04

Magnetic Lipid Nanoparticles for Targeted mRNA Delivery and Enhanced Organ-Specific Expression

Xin Jin, Qiangbin Yang, Liqiang Yang, Geng Yang, Juntao Fang, Cornelis Seinen, Mark Daniëls, Christian Snijders Blok, Arjan Barendrecht, Arnold Koekman, Mies J. van Steenbergen, Enrico Mastrobattista, Joost P. G. Sluijter, Raymond M. Schiffelers, Jiong-Wei Wang, Zhiyong Lei

Publisher page

Abstract

Targeted delivery of mRNA therapeutics offers immense potential for improving treatment efficacy while reducing off-target effects. Despite extensive efforts to develop both passive and active targeting strategies, achieving precise and efficient mRNA delivery remains a significant challenge due to rapid clearance, endosomal entrapment, and nonspecific tissue distribution. This study explores magnetic lipid nanoparticles (mLNPs) as an advanced platform for in vivo mRNA delivery. By incorporating an externally applied magnetic field to the heart and lung regions, the impact of mLNPs on the tissue biodistribution and transfection efficiency of luciferase mRNA-loaded mLNPs in mice is examined. While nonmagnetic lipid nanoparticles (nLNPs) or mLNPs without a magnetic field display expected hepatic accumulation, the application of a magnetic field significantly redirects mLNPs to the heart and lungs, as confirmed by increased bioluminescence signals in these tissues. Additionally, reduced bioluminescence is observed in off-target organs such as the liver and spleen. These findings underscore the potential of mLNPs as a precision-targeted delivery system for mRNA therapeutics, enhancing localized gene expression while minimizing systemic exposure. This work contributes to the advancement of next-generation mRNA delivery platforms, offering possibilities for targeted gene therapy and precision medicine.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Nanoparticle-Based Drug Delivery · Toxin Mechanisms and Immunotoxins

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Laboratory of CDL Research

University Medical Center Utrecht

Department of Surgery, Cardiovascular Research Institute, Nanomedicine TRP, Yong Loo Lin School of Medicine

National University of Singapore

Department of Cardiology, Laboratory of Experimental Cardiology

Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences)

Southern Medical University

Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, CG 3584, The Netherlands

UMC Utrecht Regenerative Medicine Center, Circulatory Health Research Center, University Medical Center Utrecht

Utrecht University

Department of Physiology, Yong Loo Lin School of Medicine

Funding

National Medical Research Council · Horizon 2020 Framework Programme · National University of Singapore · China Scholarship Council

References (40)

Show source-provided references
1. 10.1038/s41587-022-01491-z10.1038/s41587-022-01491-z ↗
2. 10.1038/s41568-023-00586-210.1038/s41568-023-00586-2 ↗
3. 10.1016/j.jconrel.2024.03.05610.1016/j.jconrel.2024.03.056 ↗
4. 10.1038/s41591-022-02061-110.1038/s41591-022-02061-1 ↗
5. 10.1056/NEJMoa202843610.1056/NEJMoa2028436 ↗
6. 10.1056/NEJMoa203538910.1056/NEJMoa2035389 ↗
7. 10.1021/acs.chemrev.3c0061110.1021/acs.chemrev.3c00611 ↗
8. 10.1038/d41586-021-02483-w10.1038/d41586-021-02483-w ↗
9. 10.3390/ijms25181016610.3390/ijms251810166 ↗
10. 10.1038/s41578-021-00358-010.1038/s41578-021-00358-0 ↗
11. 10.1002/wnan.200410.1002/wnan.2004 ↗
12. 10.3390/biomedicines905053010.3390/biomedicines9050530 ↗
13. 10.1038/s41578-022-00529-710.1038/s41578-022-00529-7 ↗
14. 10.3390/pharmaceutics1506160310.3390/pharmaceutics15061603 ↗
15. 10.1021/acsami.4c1181910.1021/acsami.4c11819 ↗
16. 10.1021/acsami.5c0092010.1021/acsami.5c00920 ↗
17. 10.1126/science.adk942810.1126/science.adk9428 ↗
18. 10.1038/s41565-020-0669-610.1038/s41565-020-0669-6 ↗
19. 10.1073/pnas.211627111910.1073/pnas.2116271119 ↗
20. 10.1021/acsami.4c0241510.1021/acsami.4c02415 ↗
21. 10.1016/j.jconrel.2022.01.02710.1016/j.jconrel.2022.01.027 ↗
22. 10.1016/j.jconrel.2022.05.04210.1016/j.jconrel.2022.05.042 ↗
23. 10.1073/pnas.210925611810.1073/pnas.2109256118 ↗
24. 10.1073/pnas.230780112010.1073/pnas.2307801120 ↗
25. 10.1021/acs.chemrev.5b0011210.1021/acs.chemrev.5b00112 ↗
26. 10.3390/ma1204061710.3390/ma12040617 ↗
27. 10.1021/acscentsci.9b0006010.1021/acscentsci.9b00060 ↗
28. 10.1021/bm501065q10.1021/bm501065q ↗
29. 10.3390/pharmaceutics1501029210.3390/pharmaceutics15010292 ↗
30. 10.1016/j.actbio.2021.07.02710.1016/j.actbio.2021.07.027 ↗
31. 10.1073/pnas.230780312010.1073/pnas.2307803120 ↗
32. 10.1038/s41565-019-0591-y10.1038/s41565-019-0591-y ↗
33. 10.1038/s42003-021-01728-810.1038/s42003-021-01728-8 ↗
34. 10.1021/acs.langmuir.2c0122110.1021/acs.langmuir.2c01221 ↗
35. 10.1016/j.jchromb.2021.12301510.1016/j.jchromb.2021.123015 ↗
36. 10.1016/j.biomaterials.2004.05.02210.1016/j.biomaterials.2004.05.022 ↗
37. 10.3390/nano1009181610.3390/nano10091816 ↗
38. 10.1016/j.mtadv.2024.10048410.1016/j.mtadv.2024.100484 ↗
39. 10.1039/C6CS00636A10.1039/C6CS00636A ↗
40. 10.3390/cancers1622386010.3390/cancers16223860 ↗